Related Experiment Videos
Statistics in clinical trials.
Stephanie J Green1, Donna K Pauler
1Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North MP-557, Seattle, WA 98109, USA. stephani@crab.org
Current Oncology Reports
|December 11, 2003
Summary
This review covers recent statistical advancements in clinical trials, focusing on efficient methods for phase I, II, and III studies. Innovations aim to improve trial design but may increase the risk of erroneous conclusions.
Area of Science:
- Biostatistics
- Clinical Trials
- Genomics
Background:
- Clinical trial design requires robust statistical methodologies.
- Evolving research questions necessitate advanced statistical approaches.
- Incorporating diverse outcomes and new technologies presents statistical challenges.
Purpose of the Study:
- To review recent statistical developments in clinical trial design.
- To highlight advancements in phase I, II, and III trial methodologies.
- To discuss statistical challenges posed by novel trial aspects.
Main Methods:
- Review of statistical literature and methodologies.
- Analysis of developments in dose-finding (phase I), endpoint incorporation (phase II), and efficiency (phase III) studies.
- Examination of statistical considerations for quality of life and genomics data.
Main Results:
- Phase I: Focus on efficient maximum tolerated dose estimation.
- Phase II: Incorporation of multiple endpoints and randomization explored.
- Phase III: Methods for reducing trial time and sample size investigated.
- Emerging challenges include integrating quality of life and genomic data.
Conclusions:
- Statistical innovations enhance clinical trial efficiency and scope.
- Design advancements require careful consideration of potential risks.
- Future statistical research must address complex outcomes and emerging fields like genomics.